HER2-Mediated Internalization of Cytotoxic Agents in


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
05 2020
Historique:
received: 24 02 2020
revised: 09 03 2020
accepted: 10 03 2020
pubmed: 28 3 2020
medline: 16 11 2021
entrez: 28 3 2020
Statut: ppublish

Résumé

Amplification of and oncogenic mutations in

Identifiants

pubmed: 32213539
pii: 2159-8290.CD-20-0215
doi: 10.1158/2159-8290.CD-20-0215
pmc: PMC7196485
mid: NIHMS1577191
doi:

Substances chimiques

ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

674-687

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234361
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190642
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA129243
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA217169
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA160001
Pays : United States
Organisme : NIH HHS
ID : U54 OD020355
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2020 American Association for Cancer Research.

Références

N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Oncogene. 2009 Feb 12;28(6):803-14
pubmed: 19060928
J Clin Oncol. 2019 Oct 10;37(29):2601-2609
pubmed: 31442103
J Thorac Oncol. 2019 Jun;14(6):1086-1094
pubmed: 30825613
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Cancer Cell. 2019 Oct 14;36(4):444-457.e7
pubmed: 31588020
Ann Oncol. 2004 Jan;15(1):19-27
pubmed: 14679114
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Biol Chem. 1996 Sep 13;271(37):22796-801
pubmed: 8798456
Ann Oncol. 2019 Mar 1;30(3):447-455
pubmed: 30596880
Eur J Cancer. 2019 Mar;109:28-35
pubmed: 30685684
Cancer Lett. 2016 Nov 28;382(2):176-185
pubmed: 27597738
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Lancet Oncol. 2019 Jun;20(6):827-836
pubmed: 31047804
J Thorac Oncol. 2014 Dec;9(12):1750-62
pubmed: 25247338
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Bioorg Med Chem Lett. 2016 Mar 15;26(6):1542-1545
pubmed: 26898815
Cell. 2020 Mar 5;180(5):895-914.e27
pubmed: 32142680
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Mol Cancer Ther. 2004 Dec;3(12):1605-13
pubmed: 15634654
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12847-52
pubmed: 12239347
Clin Cancer Res. 2019 Dec 15;25(24):7381-7387
pubmed: 31548342
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Nat Rev Cancer. 2010 Mar;10(3):194-204
pubmed: 20147901
Clin Cancer Res. 2019 Jan 1;25(1):64-72
pubmed: 30206164
Cancer Cell. 2014 Mar 17;25(3):282-303
pubmed: 24651011
Clin Cancer Res. 2007 Oct 15;13(20):6175-81
pubmed: 17947484
Ann Oncol. 2015 Jul;26(7):1421-7
pubmed: 25899785
EMBO J. 2002 May 15;21(10):2407-17
pubmed: 12006493
Cancer. 2019 Dec 15;125(24):4380-4387
pubmed: 31469421
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
J Thorac Oncol. 2018 Dec;13(12):1897-1905
pubmed: 30096481
Pharmacol Ther. 2019 Jul;199:188-196
pubmed: 30951733
Sci Signal. 2018 Oct 09;11(551):
pubmed: 30301790
Crit Rev Oncol Hematol. 2020 Apr;148:102906
pubmed: 32109716
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
J Pathol. 2014 Jan;232(2):219-29
pubmed: 24105684
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448
pubmed: 30979742
J Thorac Oncol. 2018 Feb;13(2):273-279
pubmed: 29313813
Lancet Oncol. 2019 Jun;20(6):816-826
pubmed: 31047803

Auteurs

Bob T Li (BT)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.
Weill Cornell Medical College, New York, New York.

Flavia Michelini (F)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Sandra Misale (S)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.

Emiliano Cocco (E)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Laura Baldino (L)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Yanyan Cai (Y)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Sophie Shifman (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Hai-Yan Tu (HY)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.

Mackenzie L Myers (ML)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Chongrui Xu (C)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.

Marissa Mattar (M)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Inna Khodos (I)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Megan Little (M)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Besnik Qeriqi (B)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Gregory Weitsman (G)

Richard Dimbleby Department of Cancer Research, King's College London, London, United Kingdom.

Clare J Wilhem (CJ)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Alshad S Lalani (AS)

Puma Biotechnology, Los Angeles, California.

Irmina Diala (I)

Puma Biotechnology, Los Angeles, California.

Rachel A Freedman (RA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Nancy U Lin (NU)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

David B Solit (DB)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Michael F Berger (MF)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Paul R Barber (PR)

Richard Dimbleby Department of Cancer Research, King's College London, London, United Kingdom.
UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom.

Tony Ng (T)

Richard Dimbleby Department of Cancer Research, King's College London, London, United Kingdom.
UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom.

Michael Offin (M)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

James M Isbell (JM)

Weill Cornell Medical College, New York, New York.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

David R Jones (DR)

Weill Cornell Medical College, New York, New York.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Helena A Yu (HA)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Sheeno Thyparambil (S)

mProbe Inc., Rockville, Maryland.

Wei-Li Liao (WL)

mProbe Inc., Rockville, Maryland.

Anuja Bhalkikar (A)

mProbe Inc., Rockville, Maryland.

Fabiola Cecchi (F)

AstraZeneca, Gaithersburg, Maryland.

David M Hyman (DM)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Jason S Lewis (JS)

Weill Cornell Medical College, New York, New York.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Radiochemistry and Molecular Imaging Probe Core, Memorial Sloan Kettering Cancer Center, New York, New York.

Darren J Buonocore (DJ)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Alan L Ho (AL)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Vicky Makker (V)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Jorge S Reis-Filho (JS)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Pedram Razavi (P)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Maria E Arcila (ME)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Mark G Kris (MG)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

John T Poirier (JT)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Ronglai Shen (R)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Junji Tsurutani (J)

Advanced Cancer Translational Research Institute, Department of Medical Oncology, Showa University, Tokyo, Japan.

Gary A Ulaner (GA)

Weill Cornell Medical College, New York, New York.
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
mProbe Inc., Rockville, Maryland.

Elisa de Stanchina (E)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Neal Rosen (N)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Molecular-Based Therapy, Memorial Sloan Kettering Cancer Center, New York, New York.

Charles M Rudin (CM)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Maurizio Scaltriti (M)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Molecular-Based Therapy, Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH